Loading...
01/10 05:42
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance, strategic partnerships, and promising product development, such as the plozasiran launch and multiple drug pipelines. Despite some uncertainties in clinical trial outcomes and regulatory claims, the overall sentiment remains positive due to solid financial health, strategic partnerships, and optimistic guidance. The market cap suggests a moderate reaction, likely resulting in a positive stock price movement of 2% to 8% over the next two weeks.
Net Loss for Fiscal Year 2025 $2 million (compared to $599 million in fiscal year 2024), a significant improvement due to increased revenue from licensing and collaboration agreements.
Revenue for Fiscal Year 2025 $829 million (compared to prior year), driven by license and collaboration agreements with Sarepta, Sanofi, and GSK. Key contributors include $697 million from Sarepta, $130 million from Sanofi, and $2.6 million from GSK.
Operating Expenses for Fiscal Year 2025 $731 million (compared to $605 million in fiscal year 2024), a 21% increase due to higher R&D expenses ($101 million increase) and SG&A costs ($25 million increase).
Cash Flow from Operating Activities $180 million net cash provided (compared to $463 million net cash used in fiscal year 2024), a $643 million positive change driven by cash received from licensing and collaboration agreements.
Cash and Investments as of September 30, 2025 $919 million (compared to $681 million as of September 30, 2024), an increase due to licensing and collaboration agreements, partially offset by ongoing cash burn.
FDA approval of REDEMPLO: REDEMPLO is Arrowhead's first FDA-approved siRNA medicine for familial chylomicronemia syndrome (FCS). It is self-administered at home via subcutaneous injection every 3 months. The drug reduces triglycerides by 80% and has a $60,000 annual price under the One-REDEMPLO pricing model.
Pipeline programs: Progress was made on zodasiran for homozygous familial hypercholesterolemia (HoFH) and ARO-DIMER-PA for atherosclerotic cardiovascular disease (ASCVD). Zodasiran is in Phase III trials, while ARO-DIMER-PA is awaiting Phase I/II trial clearance.
Obesity programs: ARO-INHBE and ARO-ALK7 are in Phase I/II trials targeting the activin pathway to reduce fat storage. Initial data for ARO-INHBE is expected in early 2026.
CNS program: ARO-MAPT targets tauopathies like Alzheimer's disease and uses a new delivery system for blood-brain barrier penetration. Preclinical studies show promising results.
Market expansion for REDEMPLO: The drug targets 6,500 FCS patients in the U.S. and potentially 750,000 patients with persistent chylomicronemia. The One-REDEMPLO pricing model ensures consistent pricing across indications.
Business development: Arrowhead earned $200M from Sarepta and $200M upfront from Novartis for licensing agreements. The Novartis deal includes up to $2B in milestone payments and royalties.
Financial performance: Arrowhead reported $829M in revenue for fiscal 2025, driven by licensing agreements. Operating expenses increased to $731M, primarily due to R&D and commercialization costs.
Cash position: The company has $919M in cash and investments, sufficient to fund operations into fiscal 2028.
Transition to commercial-stage: With REDEMPLO's approval, Arrowhead transitions into a commercial-stage company, focusing on sustainable innovation and rational drug pricing.
Partnership strategy: Arrowhead maintains a balanced pipeline with half of its programs wholly owned and half partnered, ensuring diversified growth.
Regulatory Risks: The company faces potential regulatory hurdles in expanding the label for REDEMPLO beyond genetic and clinical FCS. The success of ongoing Phase III studies (SHASTA-3, SHASTA-4, and SHASTA-5) is critical for supplemental NDA filings and label expansion.
Market Access and Pricing Challenges: While the One-REDEMPLO pricing model has received positive early feedback, there is a risk that payers may not fully appreciate the value of REDEMPLO, potentially impacting market access and adoption.
Supply Chain and Commercialization Risks: The company is transitioning into a commercial-stage entity with REDEMPLO as its first FDA-approved product. Ensuring a smooth supply chain and effective commercialization strategy is critical, especially given the high expectations from patients and healthcare providers.
Clinical Trial Risks: The success of ongoing and future clinical trials, including SHASTA-3, SHASTA-4, and SHASTA-5, is crucial for expanding REDEMPLO's indications and for other pipeline programs like zodasiran and ARO-DIMER-PA. Delays or failures in these trials could adversely impact the company's strategic objectives.
Financial Risks: Although the company has a strong financial position, the high R&D and SG&A expenses, particularly for late-stage clinical trials and commercialization efforts, could strain resources if revenue from REDEMPLO and other programs does not materialize as expected.
Competitive Pressures: The company operates in a highly competitive biotech space, particularly in the cardiometabolic and RNAi therapeutic areas. Competitors with similar or superior products could impact market share and revenue.
FDA approval of REDEMPLO: REDEMPLO has been approved as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). The company plans to expand its label to include severe hypertriglyceridemia through ongoing SHASTA-3 and SHASTA-4 Phase III studies, with data expected in Q3 2026 and potential regulatory submissions by the end of 2026.
Commercial launch of REDEMPLO: The drug is priced at $60,000 annually under the One-REDEMPLO pricing model, targeting approximately 6,500 FCS patients in the U.S. Early feedback from healthcare professionals and payers has been positive. The company is targeting 5,000 healthcare professionals for engagement and has launched a patient support program, Rely On REDEMPLO.
Pipeline development for zodasiran: The YOSEMITE Phase III trial for zodasiran, targeting homozygous familial hypercholesterolemia (HoFH), is expected to complete enrollment in 2026, with study completion in 2027 and a potential NDA filing by the end of 2027. A commercial launch is anticipated in 2028.
ARO-DIMER-PA program: A Phase I/II clinical trial for ARO-DIMER-PA, targeting atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia, is planned. This program represents a significant step forward in RNAi therapeutics and preventative cardiology.
ARO-MAPT program: A Phase I/II clinical trial for ARO-MAPT, targeting tauopathies including Alzheimer’s disease, is set to begin. This program utilizes a new proprietary delivery system for CNS penetration.
Obesity programs (ARO-INHBE and ARO-ALK7): Initial data for ARO-INHBE is expected in early January 2026, with more comprehensive data by mid-2026. Early safety and target engagement data for ARO-ALK7 will also be shared in 2026.
Business development and partnerships: The company has entered into a $200 million upfront licensing agreement with Novartis for ARO-SNCA, targeting Parkinson’s disease, with potential milestone payments up to $2 billion. Additionally, a $200 million milestone payment was earned from Sarepta for ARO-DM1.
Dividend Program: No specific mention of a dividend program was made during the conference call.
Share Repurchase: The company repurchased shares from Sarepta, reducing common shares outstanding by 2.4 million from the prior quarter.
The earnings call highlights strong financial performance, strategic partnerships, and promising product development, such as the plozasiran launch and multiple drug pipelines. Despite some uncertainties in clinical trial outcomes and regulatory claims, the overall sentiment remains positive due to solid financial health, strategic partnerships, and optimistic guidance. The market cap suggests a moderate reaction, likely resulting in a positive stock price movement of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
